Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis (NCT03211793) | Clinical Trial Compass
RecruitingPhase 1/2
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
Netherlands20 participantsStarted 2021-10-06
Plain-language summary
The MANUS Trial aims to examine the safety, feasibility and potential efficacy of intramuscularly injected allogeneic mesenchymal stromal cells as treatment for digital ulcers of systemic sclerosis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Established diagnosis of SSc according to the 2013 ACR/EULAR criteria
* At least one active digital ulcer (painful area, \>2 mm in diameter with visible depth and loss of dermis) refractory to intravenous prostacyclins
* 'Refractory to prostacyclins' is defined as
* Worsening of ulcer(s) within 1 month after prostacyclins iv
* No improvement of ulcer(s) after 2 months after prostacyclins iv, as judged by the referring physician
* Recurrence of exactly the same ulcer(s) (same location) within 3 months after prostacyclins iv
* Written informed consent
Exclusion Criteria:
* Ulcer with underlying calcinosis (ruled out by X-ray prior to screening/inclusion)
* History of neoplasm or malignancy in the past 10 years
* Pregnancy or unwillingness to use adequate contraception during study
* Serious known concomitant disease with life expectancy \<1 year
* Uncontrolled hypertension
* Uncontrolled acute or chronic infection with systemic symptoms (e.g. fever)
* Follow-up impossible